QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion--analyst

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humir...

 fda-approves-expanded-use-of-bristol-myers-squibbs-breyanzi-cancer-cell-therapy-for-previously-treated-follicular-lymphoma

FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory folli...

 bristol-myers-squibb-presents-new-4-year-sotyktu-data-demonstrate-durable-response-rates-and-consistent-safety-in-moderate-to-severe-plaque-psoriasis

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients fo...

 bristol-myers-squibb-shares-update-on-phase-3-checkmate--73l-trial-says-trial-did-not-meet-its-primary-endpoint-of-progression-free-survival-in-unresectable-locally-advanced-stage-iii-non-small-cell-lung-cancer

Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progressi...

 whats-going-on-with-medical-therapeutic-firm-aethlon-medical-on-friday

Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming ph...

Core News & Articles

Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...

 scenic-biotech-enters-into-research-collaboration-with-bristol-myers-squibb

Bristol Myers Squibb gains access to Scenic's Cell-Seq technology platform to unlock the underlying genetic interactions of...

 bristol-myers-squibb-and-repertoire-announce-18b-deal-to-reset-immune-system-in-autoimmune-patients

Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION